INTRODUCTION {#s1}
============

Colorectal cancer (CRC) ranks as the third most prevalent cancer and the third leading cause of cancer mortality worldwide \[[@R1]\]. Liver is the most common site of metastasis. Even after resection of liver metastases, more than half the patients will not be cured due to relapse of liver metastases and emergence of other distant metastases \[[@R2], [@R3]\]. Therefore, it is critical to develop metastasis-specific molecular biomarkers for patients' outcome prediction and treatment options.

MicroRNAs (miRNAs) are a class of endogenous, small (17--25 nucleotides), noncoding, single-stranded, evolutionarily conserved RNA molecules that regulate target gene expression by interfering with their transcription or by inhibiting translation. MiRNAs are known to be involved in the process of tumor cell growth, invasion and metastasis of CRC by regulating the expression of down-stream target genes \[[@R4]--[@R7]\]. Several studies reported that certain miRNAs were associated with CRC liver metastasis \[[@R4], [@R8]--[@R10]\]. For example, miR-181a and miR-200c promote liver metastases by inducing epithelial-mesenchymal transition in CRC \[[@R9], [@R10]\]. MiR-192 inhibits liver metastases by down-regulating the expression B-cell lymphoma 2, vascular endothelial growth factor A, and zinc finger E-box-binding homeobox 2 \[[@R4]\].

In our previous study, we found that miR-99b-5p was significantly more expressed in primary tumor than in matched liver metastasis. *In vitro*, miR-99b-5p was demonstrated to inhibit expression of mechanistic target of rapamycin (mTOR) by directly targeting its 3′ UTR. Moreover, miR-99b-5p was associated with a survival benefit in CRC patients with liver metastasis, suggesting that miR-99b-5p may serve as a predictive factor for metastasis and prognosis of CRC patients \[[@R8]\].

Herein, we report our metastasis-specific miRNA biomarker discovery approach which outlines the extensive miRNA difference between the primary tumor and paired liver metastasis specimens and validates newfound miRNA biomarkers in other independent cohorts of specimens. We also evaluated the correlation of the differential miRNAs expression profile with clinicopathological features and patient prognosis.

RESULTS {#s2}
=======

Differential miRNAs expression profile in primary tumros and matched liver metastasis tissues {#s2_1}
---------------------------------------------------------------------------------------------

We firstly performed miRNA microarray analysis in two pairs of matched pCRC and liver metastasis frozen specimens. The basic clinicopathological characteristics of these two patients were well matched. We identified 13 microRNAs whose expression levels differed between pCRC and liver metastasis tissues with a fold-change of \> 1.5. Among these miRNAs, seven (miR-513a-5p, miR-181a-5p, miR-182-5p, miR-613, miR-152, miR-644a and miR-550a-5p) were up-regulated and six (miR-192-5p, miR-506-3p, miR-99b-5p, miR-29a-3p, miR-27b-3p and miR-934) were down-regulated in liver metastasis tissues compared with pCRC tissues.

For the validation step, qRT-PCR assay was performed in 48 isolated pairs of pCRC and liver metastasis tissues; the clinicopathological characteristics of these 48 patients are shown in Table [1](#T1){ref-type="table"}. To extend the study, we added another four microRNAs (miR-196b-5p, miR-377, miR-200c and miR-10a-5p) with fold change between 1.3 and 1.5. As a result, four miRNAs (miR-99b-5p, miR-377, miR-200c and miR-196b-5p) were found to have significant differential expression between pCRC and liver metastasis tissues. MiR-99b-5p, miR-377 and miR-200c were down-regulated, while miR-196b-5p was up-regulated in liver metastasis tissues compared to pCRC (see Table [2](#T2){ref-type="table"}, Figure [1](#F1){ref-type="fig"} [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

###### The clinicopathological characteristics of 48 colorectal cancer patients with liver metastases

  Characteristics                          No.           Percent
  ---------------------------------------- ------------- ---------
  Gender                                                 
   Male                                    29            60.4
   Female                                  19            39.6
  Age, years                                             
  Median (SD)                              52 (28--74)   
   \< 60                                   34            70.8
   ≥ 60                                    14            29.2
  Primary tumor site                                     
   Rectum                                  17            35.4
   Colon                                   31            64.6
   pT                                                    
   2+3                                     9             18.7
   4                                       39            81.3
  pN                                                     
   0                                       12            25.0
   1                                       21            43.8
   2                                       15            31.2
  Vascular invasion                                      
   Negative                                27            62.8
   Positive                                16            37.2
   NK                                      5             
  Perineural invasion                                    
   Negative                                27            62.8
   Positive                                16            37.2
   NK                                      5             
  Differentiation                                        
   Poor/poor-moderate                      12            25.0
   moderate/moderate-high                  36            75.0
  Time of occurrence of liver metastasis                 
   Synchronous                             43            89.6
   Metachronous                            5             10.4
  Combined with other metastases                         
   No                                      41            85.4
   Yes                                     7             14.6

Abbreviations: NK, not known; NR, not reached; SD, standard deviation.

###### Expression level of miRNAs in the primary tumor and matched liver metastases of 48 colorectal cancer patients with liver metastases

  miRNA           Tumor status   Median      SEM          Foldchange (primary/ metastasis)   *p* value
  --------------- -------------- ----------- ------------ ---------------------------------- -----------
  miR-513a-5p     Primary        28.9670     7.87524      0.54                               0.113
                  Metastasis     53.6298     15.04555                                        
  miR-181a-5p     Primary        2.2210      1.11954      0.51                               0.188
                  Metastasis     4.3494      0.99962                                         
  miR-182-5p      Primary        19.8616     4.40714      1.48                               0.253
                  Metastasis     13.3865     4.96276                                         
  miR-613         Primary        64.2181     41.80958     1.20                               0.877
                  Metastasis     53.7233     52.13662                                        
  miR-152         Primary        31.6605     18.05150     9.32                               0.114
                  Metastasis     3.3972      0.93292                                         
  miR-644a        Primary        18.0385     9.14903      0.26                               0.313
                  Metastasis     69.2121     54.83062                                        
  miR\--550a-5p   Primary        179.4224    87.74360     0.51                               0.291
                  Metastasis     354.2439    219.88422                                       
  miR-196b-5p     Primary        8.8372      4.05013      0.18                               0.046\*
                  Metastasis     49.5967     20.74880                                        
  miR-10a-5p      Primary        5.4569      2.19123      0.16                               0.062
                  Metastasis     33.9821     16.66163                                        
  miR-192-5p      Primary        4304.9628   1690.66343   4.77                               0.051
                  Metastasis     903.1332    275.60286                                       
  miR-506-3p      Primary        11.2938     5.02323      1.07                               0.908
                  Metastasis     10.5453     6.00231                                         
  miR-99b-5p      Primary        8.8244      2.75573      6.77                               0.007\*
                  Metastasis     1.3043      0.29901                                         
  miR-29a-3p-     Primary        1.3543      0.90819      4.44                               0.169
                  Metastasis     0.3049      0.18774                                         
  miR-27b-3p      Primary        2.6432      0.61204      0.07                               0.170
                  Metastasis     39.7780     26.64356                                        
  miR-377         Primary        92.8067     40.17213     433.47                             0.026\*
                  Metastasis     0.2141      0.13345                                         
  miR-200c        Primary        13.4106     3.51479      3.77                               0.009\*
                  Metastasis     3.5561      0.95874                                         
  miR-934         Primary        15.6664     11.61170     1.78                               0.515
                  Metastasis     8.8113      2.47346                                         

Abbreviations: miRNA, microRNA; SEM, standard error of the mean. \**p* ≤ 0.05.

![Unsupervised hierarchical cluster analysis of the 528 differentially expressed miRNAs\
Glue Grant Human Transcriptome Array (Affymetrix, Santa Clara, CA, USA) screened the differential expression of miRNA between primary tumor and liver metastases in two pairs of fresh tissue. Green and red represent the down-regulated and up-regulated miRNAs, respectively. LM, liver metastasis; miRNA, microRNA; pCRC, primary CRC; Pt, patient.](oncotarget-08-35783-g001){#F1}

MiR-377 and miR-99b-5p expression levels serve as invasive biomarkers in pCRC patients with liver metastasis {#s2_2}
------------------------------------------------------------------------------------------------------------

To explore the clinical significance of these liver metastasis-specific miRNAs, we further validated the correlation between microRNAs and clinicopathological characteristics. Three up-regulated miRNAs (miR-99b-5p, miR-377 and miR-200c) and one down-regulated miRNA (miR-196b-5p) in pCRC compared to liver metastasis tissues were analyzed. As shown in Table [3](#T3){ref-type="table"}, increased miR-377 expression level was associated with advanced lymph node stage (*p* = 0.043). Likewise, decreased miR-99b-5p expression was positively correlated with perineural invasion in pCRC (*p* = 0.043).

###### Relationship between the expression level of miRNAs in the primary tumor and clinicopathologic parameters in 48 colorectal cancer patients with liver metastases

                                               No.           Percent   miR-377   miR-200c   miR-99b-5p   miR-196b-5p                                                               
  -------------------------------------------- ------------- --------- --------- ---------- ------------ ------------- -------- ------- ------- ------- --------- ------- -------- -------
  **Gender**                                                                                                                                                                       
  Male                                         29            60.4      133.69    64.193     0.138        9.99          2.805    0.233   9.64    3.998   0.719     12.22   6.537    0.307
  Female                                       19            39.6      30.41     22.445                  18.64         7.765            7.58    3.466             3.68    2.070    
  **Age, years**                                                                                                                                                                   
  Median (SD)                                  52 (28--74)                                                                                                                         
  \< 60                                        34            70.8      41.79     19.491     0.194        13.36         4.735    0.983   8.28    3.613   0.762     3.07    1.098    0.16
  ≥ 60                                         14            29.2      216.69    126.472                 13.53         3.864            10.15   3.668             22.83   13.215   
  **Primary tumor site**                                                                                                                                                           
  Rectum                                       17            35.4      41.92     25.288     0.354        19.59         9.081    0.319   15.34   6.992   0.178     4.85    2.225    0.472
  Colon                                        31            64.6      120.71    60.452                  10.02         2.183            5.25    1.709             11.02   6.156    
  **pT**                                                                                                                                                                           
  2+3                                          9             18.7      64.61     32.559     0.74         9.70          2.394    0.617   3.86    1.710   0.392     19.13   15.913   0.457
  4                                            39            81.3      99.31     48.982                  14.27         4.292            9.97    3.352             6.46    3.446    
  **pN**                                                                                                                                                                           
  Negative                                     12            25.0      9.23      3.215      0.043\*      15.88         5.763    0.69    12.06   6.051   0.503     13.89   12.014   0.477
  Positive                                     36            75.0      120.67    52.912                  12.59         4.308            7.74    3.103             7.15    3.732    
  **Vascular invasion**                                                                                                                                                            
  Negative                                     27            62.8      85.06     62.303     0.673        12.37         3.394    0.525   12.91   4.688   0.088     4.17    1.549    0.216
  Positive                                     16            37.2      124.78    59.972                  17.56         8.888            4.17    1.638             19.34   11.657   
  NK                                           5                                                                                                                                   
  **Perineural invasion**                                                                                                                                                          
  Negative                                     27            62.8      35.52     18.413     0.151        13.30         3.371    0.742   13.45   4.710   0.043\*   9.61    5.442    0.953
  Positive                                     16            37.2      208.38    113.022                 15.99         8.959            3.25    0.961             10.17   8.117    
  NK                                           5                                                                                                                                   
  **Differentiation**                                                                                                                                                              
  Poor/poor-moderate                           12            25.0      124.21    79.322     0.657        7.67          2.146    0.352   3.61    1.083   0.074     12.81   10.703   0.577
  Moderate/moderate-high                       36            75.0      82.34     47.093                  15.32         4.606            10.56   3.623             7.51    4.143    
  **Time of occurrence of liver metastasis**                                                                                                                                       
  Synchronous                                  43            89.6      99.78     44.722     0.616        10.84         2.265    0.432   9.08    3.048   0.786     9.77    4.505    0.507
  Metachronous                                 5             10.4      32.86     20.699                  35.48         28.185           6.60    4.063             0.85    0.300    
  **Combined with other metastases**                                                                                                                                               
  No                                           41            85.4      88.66     43.422     0.806        11.12         2.401    0.466   9.65    3.205   0.475     7.08    3.650    0.543
  Yes                                          7             14.6      117.11    113.770                 26.84         20.083           4.00    1.473             19.15   18.443   

Abbreviations: NK, not known; SD, standard deviation; SEM, standard error of the mean.

MiR-200c and miR-196-5p expression levels serve as prognostic biomarkers in pCRC patients with liver metastasis {#s2_3}
---------------------------------------------------------------------------------------------------------------

We tested the association between miRNA expression and overall survival by performing survival analysis. As shown in Figure [2](#F2){ref-type="fig"} and Table [4](#T4){ref-type="table"}, patients with elevated expression levels of miR-200c in pCRC and miR-196b-5p in liver metastases had significantly longer survival by Kaplan-Meier analysis (*p* = 0.048 and *p* = 0.02, respectively). Notably, higher expression of miR-99b-5p in pCRC also showed a better trend of survival, although statistical significance was not reached (*p* = 0.052).

![Kaplan-Meier survival curves of CRC patients subdivided by miRNAs levels in pCRC and LM tissues from CRC patients\
Overall survival analysis based on miR-377, miR-200c, miR-99b-5p and miR-196b-5p in pCRC or LM tissues are shown. The *p* value was determined by log-rank test. LM, liver metastasis; miRNA, microRNA; pCRC, primary CRC.](oncotarget-08-35783-g002){#F2}

###### Relationship between the expression level of miRNAs and overall survival in 48 colorectal cancer patients with liver metastases

                                                   95% CI                                                 95% CI            
  ----------------- ----------- --------- -------- -------- -------- ----------------- --------- -------- -------- -------- --------
  **miR-377**       Low         29.867    5.509    19.069   40.664   **miR-377**       Low       24.133   13.966   0        51.506
                    High        42.233    11.776   19.152   65.314                     High      37.067   NR       NR       NR
                    *p* value   0.761                                                  p value   0.417                      
  **miR-200c**      Low         24.133    3.290    17.684   30.582   **miR-200c**      Low       26.033   5.702    14.858   37.209
                    High        NR        NR       NR       NR                         High      48.3     12.092   24.599   72.001
                    *p* value   0.048\*                                                p value   0.266                      
  **miR-99b-5p**    Low         23.467    2.212    19.131   27.802   **miR-99b-5p**    Low       23.467   1.594    20.343   26.59
                    High        48.300    NR       NR       NR                         High      48.3     12.096   24.592   72.008
                    *p* value   0.052                                                  p value   0.098                      
  **miR-196b-5p**   Low         23.467    1.71     20.115   26.819   **miR-196b-5p**   Low       21.633   1.686    18.329   24.937
                    High        42.233    NR       NR       NR                         High      NR       NR       NR       NR
                    *p* value   0.116                                                  p value   0.02\*                     

Abbreviations: CI: confidence interval; miRNA, microRNA; NR: not reached; OS, overall survival; SEM, standard error of the mean. \**p* ≤ 0.05.

DISCUSSION {#s3}
==========

Patients with liver metastasis in CRC were with a poor prognosis and early recurrence. Previous researches in the fields of molecular and genetic studies have contributed to our understanding of CRC liver metastasis in the cellular level \[[@R11], [@R12]\]. However, heterogeneity of research methods as well as tumor tissue acquisition limited the diagnostic and prognostic role of specific genes in metastases.

Recent findings have highlighted the role of miRNAs in the tumorigenesis of CRC cells acting as oncogenes or tumor suppressor genes \[[@R13], [@R14]\]. Similar studies have been performed to gain better insight into genomic changes involved in pCRC initiation and progression \[[@R15]\]. However, there are few studies of miRNA expression accounting for distant metastasis of pCRC. In this study, we aim to identify a differential microRNA expression profile in pCRC and their matched liver metastasis.

In this study, expression profiling of 1036 miRNAs based on an RNA array platform in clinical samples of pCRC tissues with matched liver metastasis tissues was carried out to identify advanced CRC signatures and to use miRNA expression profiles to classifying CRC with liver metastasis. The confirmation of the array data was done by using qRT-PCR. The results, by microarray analysis in two paired colorectal cancers, showed 17 miRNAs were dysregulated in liver metastasis tissues compared with pCRC tissues. These differentially expressed miRNAs were further validated by qRT-PCR in 48 isolated pairs of pCRC and liver metastasis tissues, and four miRNAs (miR-99b-5p, miR-377, miR-200c and miR-196b-5p) were found to have significant differential expression between pCRC tissues and liver metastasis tissues. While examining the potential clinical impact of these four liver metastasis-specific miRNAs, we noticed that up-regulation of miR-200c in pCRC tissues and miR-196b-5p in liver metastasis tissues were associated with significantly longer survival by Kaplan-Meier analysis (*p* = 0.048 and *p* = 0.02, respectively).

We previously demonstrated that miR-99b-5p is a tumor suppressing miRNA in metastatic CRC, and that its suppressive effects are mediated chiefly by suppressing mTOR expression \[[@R8]\]. MiR-196b was reported to be highly expressed in CRC tissues and was correlated with rapid progression and poor prognosis \[[@R16], [@R17]\]. MiR-196b was also a predictive factor in palliative chemotherapy and neoadjuvant radiochemotherapy \[[@R18], [@R19]\]. Similar to our findings, high expression of miR-200c was observed in liver metastasis \[[@R10]\] and its expression in serum was reported to be a prognostic factor in patients with CRC \[[@R20]\]. It has been found that miR-200c could mediate epithelial-mesenchymal transition in liver metastases by regulating the TGF-TGFegu signal pathway \[[@R21], [@R22]\]. MiR-377 was a novel biomarker for poor prognosis in gastrointestinal cancer, which induced tumorigenesis by targeting multiple tumor-suppressor genes \[[@R23]\].

Our study is distinct from previous studies in several aspects. First, we directly compared pCRC and matching liver metastasis tissues from the same patients, which avoid heterogeneity due to distinct miRNA from different patients. Second, to improve the predictive value of the miRNA markers, we developed a miRNA-based classifier panel rather than just suggesting each miRNA as a predictor.

In conclusion, four miRNAs (miR-99b-5p, miR-377, miR-200c and miR-196b-5p) were found to be differently expressed between primary tumors of patients with CRC and their matched liver metastases. Moreover, we nominate the candidate microRNAs, miR-200 and miR-196b-5p as potential prognostic markers. Our study suggested that these miRNAs could hopefully serve as metastasis-specific miRNA biomarkers for the management of patients with CRC.

MATERIALS AND METHODS {#s4}
=====================

Patient samples {#s4_1}
---------------

The fresh-frozen/formalin-fixed, paraffin-embedded primary CRC and matched corresponding liver metastatic tissues were collected from 2004 to 2012 in the Department of Colorectal Cancer, Fudan University Shanghai Cancer Center. The tissue bank of the hospital stored the specimens. The study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center and written informed consent was obtained from all patients.

RNA extraction and miRNA array hybridization {#s4_2}
--------------------------------------------

Total RNAs from two CRC patients with liver metastasis were analyzed by microarray. Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA, USA). RNA was labeled and hybridized to Glue Grant Human Transcriptome Array (Affymetrix, Santa Clara, CA, USA) \[[@R24]--[@R26]\] according to manufacturer\'s instructions. Command Console^®^ Software version 3.1 was used for microarray analysis. A total of 1036 miRNAs were covered using miRBase version 18.0.

Quantitative real-time polymerase chain reaction {#s4_3}
------------------------------------------------

miR-513a-5p, miR-181a-5p, miR-182-5p, miR-613, miR-152, miR-644a, miR-550a-5p, miR-192-5p, miR-506-3p, miR-99b-5p, miR-29a-3p, miR-27b-3p, miR-934, miR-196b-5p, miR-200c, miR-377, miR-10a-5p and RNU6B (internal control) specific cDNA syntheses were carried out using the miScript Reverse Transcription Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s protocols. The expression level of miRNAs above was measured using TaqMan miRNA assays (Applied Biosystems, Carlsbad, CA, USA). U6 was used as an endogenous control and the fold change was calculated using the 2^−ΔΔCt^ method.

Statistical analysis {#s4_4}
--------------------

The data were analyzed with SPSS version 18.0. The student *t*-test and one factor analysis of variance were used for analysis as appropriate. Kaplan-Meier method and log-rank test were used to estimate the survival. *P* \< 0.05 was considered statistically significant.
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